Jerusalem, 2 July, 2025 (TPS-IL) — Tel Aviv-based RedHill Biopharma has begun recruiting patients for a Phase 2 trial testing its experimental drug opaganib with darolutamide in men with advanced prostate cancer. The study, led by Professor Lisa Horvath and run by ANZUP, will enroll 60 patients across Australia and New Zealand. It uses a special blood test to find patients most likely to benefit from the treatment.
Supported by Bayer and the Ramsay Hospital Research Foundation, the trial aims to improve outcomes in men with hard-to-treat prostate cancer. This marks a key step in RedHill’s efforts to bring Israeli-developed cancer treatments to the global market.